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 Abstract 
 Background/Aims: Ruthenium plaques are used for the treatment of ocular tumors. There is, 
however, a controversy regarding the maximum treatable tumor height. Some advocate ec-
centric plaque placement, without a posterior safety margin, to avoid collateral damage to 
the fovea and optic disc, but this has raised concerns about marginal tumor recurrence. There 
is a need for quantitative information on the spatial absorbed dose distribution in the tumor 
and adjacent tissues. We have overcome this obstacle using an approach based on Monte 
Carlo simulation of radiation transport.  Methods: CCA and CCB  106 Ru plaques were modeled 
and their geometry embedded in a computerized tomography scan of the eye of a patient. 
Different tumor sizes and locations were simulated with the general-purpose Monte Carlo 
code PENELOPE.  Results: Cumulative dose-volume histograms were obtained for the tumors 
and the tissues at risk considered. Plots of isodose lines for both plaques were obtained in a 
computerized tomography study.  Conclusions: Ruthenium eye plaques are an adequate 
treatment option for tumors up to around 5 mm in height. According to our results, assuming 
a correct placement of the plaque, a tumor of 6.5 mm apical height is about the maximum 
size that can be treated safely with the large CCB plaque.  © 2014 S. Karger AG, Basel 
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 Introduction 
 Uveal melanoma is a common intraocular tumor in adults. Brachytherapy with  106 Ru 
plaques is one of the treatments intended to preserve the eye and to maintain visual acuity to 
some extent  [1] . The surgical technique for placing an eye plaque consists of a full or partial 
peritomy for exposing the sclera in the tumor area. Then any eye muscle in the base of the 
melanoma must be disinserted. Some surgeons opt to disinsert muscles even if they are not in 
the tumor base in order to facilitate the placement of the plaque, particularly in posterior tumor 
locations  [2] . It is common practice to place the plaque centrically over the tumor, overlapping 
its base by at least 2 mm in all directions  [3] . However, some surgeons choose an eccentric 
location of the plaque either when anatomical structures around the eye do not facilitate a 
centric placement or in situations in which a centric location could result in a large dose to 
structures at risk such as the papilla, the optic nerve, the fovea, the macula or the eye lens  [3] .
 The tumor control rates, number of patients with preserved useful vision, risk of local 
recurrence, number of metastases, number of enucleations and survival rates after brachy-
therapy with  106 Ru plaques vary from one research group to another  [3–8] . Some groups have 
concluded that  106 Ru plaques are of limited use  [5, 9] , while another group considers these 
plaques adequate even when used in eccentric placements or for large tumors whose height 
exceeds 5 mm  [10] . There are many reasons why the rate of treatment failure shows large 
variation, from 5 up to 40%, depending on the study considered. Some of these reasons are: 
(1) each research group uses different criteria for selecting patients to be treated with  106 Ru 
plaques based on tumor size and location  [8, 11] ; (2) different surgical techniques for plaque 
placement are employed, with some groups routinely disinserting any extraocular muscle 
affecting the position of the plaque; (3) some groups confirm the plaque position after surgery, 
while others do not  [12] , and (4) different dose prescriptions for the tumor are given, with 
minimum apical doses ranging from 60 to 130 Gy. These discrepancies reflect that, in general, 
there is no full consensus on critical aspects of the treatment such as patient eligibility, 
maximum tumor size and location, surgical techniques, plaque placement, delivered dose and 
adjuvant therapies  [13, 14] .
 A vast literature is available on the adequacy of  106 Ru plaques for the treatment of uveal 
melanomas (see Pe’er  [2] and the references therein). However, most published works base 
their conclusions on retrospective clinical studies. There is a lack of knowledge about the 
spatial absorbed dose distribution in the structures at risk and in the tumor volume  [15] . 
Quantitative knowledge about the spatial dose distribution in the tumor and in the structures 
at risk is necessary, although not sufficient, for determining the reasons for the success or 
failure of the therapy in a given patient, and it is also desirable for improving the technique 
of placement of the plaque.
 For almost three decades, the Monte Carlo simulation of radiation transport has been 
used to estimate the absorbed dose in radiotherapy patients  [16] . The Monte Carlo estimation 
of dose absorption is regarded as one of the most accurate dose computation methods. In 
particular, the results obtained with Monte Carlo simulations for small radiation fields, like 
the ones required for eye irradiation, are more accurate than those computed with analytical 
or semi-analytical algorithms  [17, 18] . However, until recently, to the best of our knowledge, 
only six published studies had mainly focused on the use of Monte Carlo simulations to 
estimate the dose delivered by  106 Ru plaques  [19–24] . All six works estimated the dose in a 
spherical homogeneous water phantom, disregarding the anatomical structure of the eye and 
the orbit.
 We present results from a Monte Carlo algorithm of radiation transport that incorporates 
a realistic model of a plaque embedded in a computerized tomography scan of the eye while 
simulating the continuous beta decay spectrum. The scope of this study was to simulate a 
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generalized case from which general conclusions about the treatment with ruthenium plaques 
can be derived. In particular, we aimed at giving guidance on the largest tumor height value 
that can be treated with a  106 Ru plaque based on dosimetric results obtained from the simu-
lations, taking into account the centric or eccentric placement of the plaque. Our simulations 
computed the spatial absorbed dose distribution in the computerized tomography scan of a 
patient, allowing obtaining isodose maps and dose-volume histograms for the target volume 
and structures at risk. These maps and histograms provide quantitative information on the 
treatment that up until now has not been available.
 Materials and Methods 
 Simulation Codes 
 The radioactive isotope  106 Ru decays into  106 Rh, producing a beta spectrum with a maximum energy of 
39 keV and a half-life of 368 days.  106 Rh then decays into stable  106 Pd, producing a beta spectrum with a 
maximum energy of 3.540 MeV and a half-life of 29.8 s. This latter disintegration is used for therapeutic 
purposes. Simulations were run with the Monte Carlo general-purpose radiation transport code PENELOPE 
 [25, 26] using penEasy  [27] as the main steering program. penEasy is not prepared for simulating a spectrum 
resulting from a beta decay; therefore, the original code was modified to simulate the decay of  106 Rh into 
 106 Pd through the five disintegrations with the highest yields, i.e. 3.540 MeV (78.6%), 3.050 MeV (8.1%), 
2.410 MeV (10.0%), 2.000 MeV (1.77%) and 1.539 MeV (0.46%)  [28] . For each primary particle sampled, an 
endpoint energy was chosen at random according to the probabilities given by the yields. The initial electron 
energies were then sampled at random from the corresponding beta decay spectrum. The beta decay spectra 
were generated with an adapted version of the code EFFY  [29] incorporated in the modified penEasy code. 
EFFY calculates beta spectra from the Fermi theory of beta decay, taking shape factors into account.
 Geometry of the Plaques 
 The eye plaques we used for this study were models CCA and CCB produced by the manufacturer BEBIG 
(Eckert & Ziegler BEBIG, Berlin, Germany). These plaques are shaped like truncated spherical shells. The inner 
radius of the shells, along the symmetry axis, is 12.0 mm. The outer diameters of the shells, across the rim, are 
15.5 and 20.2 mm for the CCA and the CCB plaques, respectively. Both shells are 1.0 mm in thickness and are 
divided into 3 layers. The thicknesses of these layers from the inner to the outer surface of the shell are 0.1, 
0.2 and 0.7 mm. All layers are made of silver, with the middle layer containing the emitter substance. However, 
the emitter substance does not cover the whole shell, falling short of the shell rim by 0.7 mm. With the exception 
of the diameter across the shell, all other dimensions are equal for the CCA and the CCB plaques. The geome-
tries of the plaques were modeled using the constructive quadric geometry package provided by PENELOPE, 
which defines bodies by grouping quadric surfaces (spheres, planes, etc.). The distribution of the emitter 
substance was assumed to be homogeneous. The accuracy of our simulation system for eye plaques was previ-
ously validated by comparison of our simulated data in a water phantom with experimental results  [30] .
 Voxelized Geometry 
 A computerized tomography scan of the eye of an anonymized adult patient was used as a voxelized 
human phantom. The size of an emmetropic eyeball does not show large variation from one individual to 
another  [31] . It is, therefore, justified to employ a phantom based on only one individual for the investigation 
we are presenting, whose scope is to allow general conclusions on the dose distribution obtained using a 
generalized model. The axial length of the eye employed in this study was 22.8 mm. Earlier versions of this 
phantom were already used in previous works  [32, 33] . The computerized tomography scan had 256 × 256 
× 59 voxels of 0.03125 × 0.03125 × 0.1 cm size. Hounsfield units of the original computerized tomography 
were converted into mass density values via the calibration curve of the computerized tomography scanner. 
For material assignment, three media were considered: water, air and bone. Provided the mass density of 
each voxel is correctly assigned through the calibration curve of the scanner, the approximation of different 
soft tissues to water produces compatible doses within the standard statistical uncertainty (2%) reached in 
the simulation results. A distinctive feature of penEasy is the possibility of simulating quadric geometries 
superimposed on voxelized geometries. This feature allows the simulation of the geometry of the eye plaque, 
defined as a spherical shell, positioned inside the voxelized human phantom.
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 Tumors, Plaque Locations and Organs at Risk 
 The basal extent of a tumor determines the size of the eye plaque to be used, with larger plaques used 
for tumors with larger basal extension. The apical height of a tumor determines the applicability of  106 Ru eye 
plaques, which in its turn is dictated by the penetration depth of the electrons derived from the beta decay 
process. Following this reasoning, we decided to study the treatment using idealized tumor volumes, the 
apical height of which we varied while keeping their basal diameter constant. The idealized tumor volumes 
were segmented in the computerized tomography scan with a paraboloid truncated by a sphere representing 
the inner scleral surface. The sclera was defined by means of a spherical shell of a thickness of 1.7 mm. The 
height of the tumor did not include the thickness of the sclera.
 Although spheres and paraboloids were used as boundary surfaces in the segmentation process of the 
sclera and the tumor volumes, these structures (i.e. sclera and tumors) were actually defined in the comput-
erized tomography study; this means that a voxel divided by a boundary surface was either assigned to the 
corresponding structure or to the ‘outside’. The immediate consequence of this voxelized definition of the 
structures is that the thickness of the sclera is not constant, ranging from approximately 1.2 mm to approxi-
mately 2.1 mm depending on the number of voxels that are included between the two boundary spherical 
surfaces used for defining the sclera at any location. The chosen scleral thickness, although larger than that 
normally seen in patients, gives a safety margin of about 0.5 mm. Additionally, the chosen thickness is in 
agreement with the default value of 1.5 mm employed in the code EYEPLAN  [34, 35] .
 The same situation as described for the definition of the sclera arises when defining the tumor volumes. 
Owing to the voxelized nature of the segmented tumor volumes, all reported tumor apical heights lie within 
±0.5 mm of the quoted value. In contraposition, it must be stressed that the geometry of the eye plaques was 
actually modeled as a spherical shell and embedded in the computerized tomography scan; thus, the thickness 
of the eye plaques is constant. Other segmented structures of the eye for this study were the cornea, the lens 
and the optic disc. The structures in the orbit that were segmented in this model were the optic nerve and 
the lacrimal gland.
 All tumor models were done nasally from the optic nerve. The symmetry axes of the tumors were made 
coplanar with the computerized tomography axial plane where the eyeball showed its largest diameter. 
Tumors were placed in 3 nasal (i.e. medial) locations: equatorial, anterior (i.e. pre-equatorial) and posterior 
(i.e. postequatorial). Equatorial tumors have their symmetry axis along the eyeball equator, which was deter-
mined to be 15° above an imaginary horizontal axis (with respect to the computerized tomography) passing 
through the center of the eyeball. The anterior location was set at 15° above the equator, i.e. 30° above the 
horizontal axis. The posterior location was set 45° below the equator, i.e. 30° below the horizontal axis. All 
tumors had a basal diameter of 10 mm. Five tumor heights were considered for the equatorial location, 
namely 3, 5, 6.5, 7 and 7.5 mm. The apical height of the anterior and posterior tumors was set at 3 mm in both 
cases.
 Eye plaques were placed according to tumor position. With the pre-equatorial and equatorial tumors, 
the CCA plaque was placed centrically with respect to the tumor. With the postequatorial tumor, the CCA 
plaque was placed eccentrically with respect to the tumor, with its symmetry axis 15° below the horizontal 
axis instead of 30°. The CCB plaque was only placed in the equatorial position (centric to the equatorial 
tumors).  Figure 1 shows the positions of the plaques and the tumors.
 Dose Prescription 
 The simulations run with PENELOPE estimated the absorbed dose at each voxel of the computerized 
tomography scan. The computed dose is expressed in units of electron volt per gram per primary particle. 
These units can be converted to milligrays per megabecquerel-hours. The dose in gray can then be obtained 
by knowing the activity of the plaque in megabecquerel and the irradiation time in hours. The activities of 
the CCA and CCB BEBIG plaques, as quoted by the manufacturer, are 13.7 and 25.9 MBq, respectively.
 To determine the irradiation time, we used the following dose prescription method. The time required 
for achieving a dose of 700 Gy to the sclera is calculated. If the tumor apex receives a dose greater than 100 
Gy, the treatment is performed using that time. If not, then the irradiation time is increased until the apical 
dose is 100 Gy. If, however, the new time results in a scleral dose exceeding 1,500 Gy, then the  106 Ru plaque 
is rejected and other plaque models or alternative treatments are considered. The apical minimum dose 
chosen for the present study (100 Gy) was a compromise between the apical dose commonly used in many 
hospitals, i.e. between 80 and 100 Gy, and that prescribed at the Universitätsklinikum Essen, which is 130 
Gy. Usage of the prescription of 700 Gy to the sclera gives a reasonable allowance for uncertainties associated 
with the measurement of the apical height of the tumor or with the process of plaque placement.
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 The apical and scleral doses reported from Monte Carlo simulations in this work are absorbed doses at 
a voxel. In the case of the apical dose, the voxel belonging to the tumor volume located at the greatest distance 
from the eye plaque is used. For the scleral dose, the voxel belonging to the segmented sclera closest to the 
eye plaque and located along the symmetry axis of the plaque is used. The described dose prescription 
method was employed to calculate the apical tumor and scleral doses for each tumor if treated with the CCA 
and the CCB plaques by means of the spatial dose distributions obtained with the PENELOPE simulations 
( table 1 ).
 Assessment of the various treatments was done using isodose curves and cumulative dose-volume 
histograms. In order to calculate the latter, the aforementioned segmentation of the tumor volumes and the 
structures at risk was used in conjunction with the spatial dose distributions estimated with the PENELOPE 
simulations. Cumulative dose-volume histograms plotted the percentage of the volume of the segmented 
structure that receives a dose equal to or greater than the value in the abscissa. In the cases of eccentric 
plaque placement, the irradiation time used was that of the corresponding centric irradiation, with the 
exception of the posterior tumor irradiation for which all placements are eccentric.
a b
c d
 Fig. 1. Isodose lines plotted on the slice coplanar with the plaques’ symmetry axes. Metric scales are in cen-
timeters. The cross-sections of the plaques are drawn in green (colors in online version only) with the emit-
ter layers in red. The labels of the isodose lines are given in gray (Gy). Tumors are shown as translucent areas. 
Other tumor sizes can be inferred by the reader using the accompanying metric scales.  a Equatorial 3-mm 
tumor treated centrically with the CCA plaque.  b Equatorial 6.5-mm tumor treated centrically with the CCB 
plaque.  c Equatorial 3-mm tumor treated eccentrically from the anterior position with the CCA plaque; the 
anterior tumor is also shown.  d Equatorial 3-mm tumor treated eccentrically from the posterior position 
with the CCA plaque; the posterior tumor is also shown. 
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 Results and Discussion 
 Study of Tumor Size 
 Small Tumors (3 and 5 mm Apical Height) 
 The dependency of cumulative dose-volume histograms on tumor height is reproduced 
in  figure 2 a, which shows plots corresponding to equatorial tumors treated centrically. Only 
the 3-mm ( fig. 1 a) and the 5-mm tumors are adequately treated. For the 3-mm tumor and 
CCA plaque, 100% of the tumor volume receives a dose of at least 140 Gy. Our modeled 
5-mm-thick tumor can be treated with either the CCA or the CCB plaque, both of which 
deliver a dose of at least 100 Gy to 100% of the tumor volume, which is the prescribed 
minimum dose ( fig. 2 a). The dose coverage is slightly better with the CCB plaque. The risk of 
collateral damage to the optic disc, however, is smaller with the CCA plaque. Treating a 
5-mm-thick equatorial tumor would deliver 50–200 Gy to 20% of the optic disc volume if a 
CCB plaque were used ( fig. 3 a, histogram ‘CCB equator, 5 mm’), as compared with a maximum 
of only 30 Gy being delivered to the whole optic disc with a CCA plaque ( fig. 3 a, histogram 
‘CCA equator, 5 mm’).
 Medium Tumors (6.5 mm Apical Height) 
 The treatment of a 6.5-mm-thick equatorial intraocular tumor is shown in  figures 1 b 
and  2 a. Of the two plaques studied, neither can be used for the treatment of this tumor 
without exceeding the 1,500-Gy limit to the sclera ( table 1 ). Cumulative dose-volume 
histograms of the tumor are plotted for each plaque in  figure 2 a (histograms ‘CCA, 6.5 
mm’ and ‘CCB, 6.5 mm’). If treatment of the 6.5-mm tumor with the CCB plaque were 
accepted with a dose to the sclera of 1,787 Gy, the entire tumor volume would receive the 
minimum prescribed dose of 100 Gy, but 40% of the tumor volume would absorb doses 
ranging from 1,000 to 1,500 Gy, with sight-threatening doses being delivered to the lens, 
optic disc and cornea ( fig. 1 b)  [36–39] . The optic nerve would also receive a dose similar 
to that to the optic disc, whereas the lacrimal gland would receive a tolerable dose of only 
3 Gy.  Figure 3 shows how the dose-volume histograms for the optic disc and the lens, 
respectively, increase with the size of the plaque and the proximity of placement to the 
structure at risk.
 Location Height, 
mm
Plaque Sclera, 
Gy
Apex, Gy Time, 
h
Anterior 3 CCA 700 128 96
Posterior 3 CCA 700 100 109
Equatorial 3 CCA 700 153 116
Equatorial 3 CCB 700 161 107
Equatorial 5 CCA 1,361 100 227
Equatorial 5 CCB 892 100 171
Equatorial 6.5 CCA 3,083 100 514
Equatorial 6.5 CCB 1,787 100 343
Equatorial 7 CCA 6,249 100 1,041
Equatorial 7 CCB 3,032 100 581
Equatorial 7.5 CCA 6,856 100 1,142
Equatorial 7.5 CCB 3,058 100 586
Doses to the sclera exceeding the 1,500-Gy limit are typeset in 
italics.
 Table 1.  Dose prescription for 
the different tumor locations, 
tumor apical heights and plaque 
models
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 Large Tumors (7 and 7.5 mm Apical Height) 
 The irradiation of tumors larger than 6.5 mm in apical height either with the CCB or the 
CCA plaque would require a dose greater than 2,000 Gy to the sclera ( table 1 ), which is not 
acceptable according to the dose prescription method used at Essen. The cumulative dose-
volume histograms of the lens, optic disc and cornea ( fig. 2 b) for a tumor 7 mm in apical height 
also reveal excessive doses to these structures at risk  [35–38] .
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 Fig. 2.  a Cumulative dose-volume histograms for equatorial tumors of different sizes, all irradiated centri-
cally with equatorial plaque placement. Each histogram label indicates the plaque used and the height of the 
treated tumor. ‘CCB plaque, 7.5 mm’ is not shown, since it is similar to the 7-mm case.  b Cumulative dose-
volume histograms for structures and organs at risk if a 7-mm equatorial tumor is irradiated centrically with 
a CCB plaque. 
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 Fig. 3. Cumulative dose-volume histograms obtained for ocular structures at risk. Each histogram label indi-
cates the plaque used, its placement and the tumor height.  a Dose-volume histograms for the optic disc.
 b Dose-volume histograms for the lens. 
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 Eccentric Treatment 
 Anterior Tumor 
 Figure 4 a (histogram ‘CCA anterior’) shows that if a 3-mm-thick tumor is treated with a 
centrically placed CCA plaque, 100% of the tumor volume receives a dose of at least 130 Gy. 
However, with the same tumor treated with an eccentrically placed CCA plaque (i.e. equa-
torial plaque with pre-equatorial tumor), the dose delivered to the lens is reduced by 80% 
( fig. 4 d, histograms ‘lens, CCA anterior’ and ‘lens, CCA equator’;  fig. 1 a), albeit at the cost of 
reducing the dose to the tumor to 50 Gy ( fig. 4 a, histogram ‘CCA equator’). If a 3-mm-thick 
pre-equatorial tumor is treated with an eccentrically placed CCB plaque, the tumor receives 
the same dose that it would absorb with a centrically placed CCA plaque ( fig. 4 a, histograms 
‘CCB equator’ and ‘CCA anterior’), but the lens absorbs slightly more of the dose, i.e. up to an 
additional 10% ( fig. 4 d, histograms ‘lens, CCB equator’ and ‘lens, CCA anterior’).
 Equatorial Tumor 
 Following our dose prescription method, a 3-mm equatorial tumor receives a minimum 
dose of 135 Gy if treated with a CCA plaque, whether this plaque is positioned equatorially or 
pre-equatorially ( fig. 4 b, histograms ‘CCA equator’ and ‘CCA anterior’;  fig. 1 c, a). For tumors 
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tumor.  d Structures at risk obtained with irradiation of the 3-mm melanomas. 
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with an apical height of 3 mm or less, it follows that eccentric placement with the edge of the 
plaque aligned with the lateral tumor margins is acceptable and is equivalent in terms of dose 
coverage to the tumor to centric treatment in which the plaque overlaps the tumor by at least 
2 mm in all directions. It must be remembered that the emitter in the eye plaque does not 
cover its full surface but falls short of the rim of the plaque by 0.7 mm. Therefore, a plaque 
aligned with the tumor edge leaves an area uncovered by the emitter substance. It is reas-
suring that, despite this uncovered area of the tumor base, the dose coverage to a tumor 
obtained with eccentric treatment does not differ from that reached with centric treatment 
for tumors of apical heights of less than 3 mm.
 Posterior Tumor 
 Figure 4 c shows the cumulative dose-volume histograms obtained for the 3-mm posterior 
tumor if irradiated eccentrically from a posterior placement with a CCA plaque (histogram 
‘CCA posterior’) and with a larger eccentricity from an equatorial placement with a CCB 
(histogram ‘CCB equator’) or a CCA (histogram ‘CCA equator’) plaque. If the eccentric 
placement implies that the plaque does not cover 2 mm or more of the tumor base, there are 
parts of the tumor that do not receive the minimum dose prescribed ( fig. 1 d). This holds true 
even for treatments done with a plaque larger than necessary, as is the case in this eccentric 
treatment of a tumor of 3 mm apical height with a CCB plaque. An eccentric irradiation of the 
posterior tumor from a posterior CCA plaque delivers a maximum dose of about 550 Gy to the 
optic disc ( fig. 4 d, histogram ‘optic disc, CCA posterior’), with the tumor absorbing a dose of 
at least 100 Gy ( fig. 4 c, histogram ‘CCA posterior’;  fig. 1 b). A small posterior melanoma is 
particularly problematic. An eccentric treatment from a posterior placement provides the 
minimum prescribed dose to the whole tumor volume at the expense of a large dose to the 
optic disc and the optic nerve.
 Conclusions 
 With respect to the currently available treatment planning system, the advantage of the 
presented method of computing the dose distribution from a  106 Ru plaque on an eye is the 
possibility of obtaining dose-volume histograms for the planned target volume and struc-
tures at risk. This information allows the oncologist to better assess the adequacy of the 
treatment. An additional benefit of our method derives from the more accurate dose distri-
bution achieved, since for its computation the real geometry as found in a patient as well as 
its inhomogeneous mass density distribution can be taken into account.
 If the method is applied to a generalized phantom, as was done in our study, some general 
conclusions can be drawn. These conclusions must of course be put into perspective consid-
ering the abovementioned assumptions of the model and the dose prescription method 
followed at the Universitätsklinikum Essen. Our study suggests a large therapeutic window 
for the safe use of  106 Ru plaques for tumors with apical heights of less than 3 mm. The choice 
of plaque size will depend on the tumor dimensions and adjacent ocular structures at risk. 
Tumors with apical heights of 3 mm or less are adequately treated with CCA plaques if the 
tumor base is completely covered by the plaque. For tumors with apical heights between 3 
and 5 mm, the  106 Ru plaque should overlap the tumor base by 2 mm. Tumors between 5 and 
6.5 mm in thickness are, in principle, treatable with  106 Ru plaques, provided there exists an 
accurate knowledge of the tumor dimensions including subclinical lateral extensions. 
Furthermore, tumors of this size require accurate positioning of the plaque. Both conditions 
are difficult to meet, and thus the treatment of tumors more than 5 mm thick may increase 
the probability of local recurrence.
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